Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.56B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 1.86M
Average 3.08M
SRPT Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Sarepta Therapeutics, Inc.NASDAQ: SRPT
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $241K fell 98.1% year over year, ahead of the -256.8% change in trailing-twelve-month financing cash flow.
Context
- Financing cash flow amounted to 7.7% of revenue in FY2025, up 1.1 pp from a year earlier.
- Financing cash flow increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -98.1% holds above the trailing-twelve-month pace of -256.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (168.34M) USD
- Year-over-year change
- -234.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (168.34M) | -234.9% |
| FY2024 | 2024-12-31 | 124.81M | -0.2% |
| FY2023 | 2023-12-31 | 125M | -46.2% |
| FY2022 | 2022-12-31 | 232.51M | -58.6% |
| FY2021 | 2021-12-31 | 561.57M | — |
Financing Cash Flow vs competitors
How SRPT compares with its peers on the latest reported figures
- SRPT's LTM Mar 2026 financing cash flow of $180.57M is the 8th largest of the 11 companies compared; the peer median is $247.03M.
- Its year-over-year change of -256.8% is the 10th highest of 11, against a peer median of +135.8%.
- Financing cash flow amounts to 8.3% of revenue for SRPT, versus a peer median of 53.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $713.47M | +170.6% | +187.7% | — | |
| LTM Jun 2026 | $536M | +2312.8% | +25.4% | 53.1% | |
| LTM Mar 2026 | $489.54M | +101.0% | +93.7% | 681.8% | |
| LTM Jun 2026 | $364.24M | -257.3% | — | 7.6% | |
| LTM Sep 2026 | $261.93M | +546.0% | — | 27.3% | |
| LTM Mar 2026 | $250.31M | +66.3% | +271.0% | — | |
| LTM Mar 2026 | $243.75M | +18.9% | +37.5% | — | |
| LTM Mar 2026 | $180.57M | -256.8% | — | 8.3% | |
| LTM Mar 2026 | $165.06M | +31.3% | -31.7% | 249.7% | |
| LTM Mar 2026 | $109.5M | +6044.6% | -1.3% | — | |
| LTM Mar 2026 | $45.65M | +8746.7% | +378.4% | — | |
| Peer median (excluding SRPT) | $247.03M | +135.8% | +65.6% | 53.1% | |
Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (418.78M) | (703.49M) | (535.98M) | 235.24M | (713.41M) |
| Depreciation & Amortization | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M |
| Deferred Income Tax | 15.81M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 113.94M | 233.02M | 182.51M | 184.3M | 123.4M |
| Change in Working Capital | (98.17M) | (39.47M) | (481.09M) | (716.61M) | 78.04M |
| Accounts Receivables | (51.65M) | (61.64M) | (185.7M) | (201.66M) | 203.76M |
| Inventory | (83.77M) | (50.78M) | (147.71M) | (395.17M) | (301.09M) |
| Accounts Payables | 23.3M | 147.57M | (50.14M) | 110.65M | 104.27M |
| Other Working Capital | 13.96M | (74.62M) | (97.54M) | (230.42M) | 71.11M |
| Other Non-Cash Items | (94M) | 142.73M | 289.16M | 53.56M | 261.98M |
| Operating Cash Flow | (443.17M) | (325.35M) | (500.99M) | (205.79M) | (205.48M) |
| Capital Expenditures | (38.49M) | (32.25M) | (87.35M) | (146.96M) | (101.97M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (29.99M) | (1.94B) | (2.05B) | (1.1B) | (44.66M) |
| Sales of Investments | 466M | 923.22M | 1.87B | 2B | 469.97M |
| Other Investing Activities | 97.89M | (1.43M) | 90.76M | (10M) | (253.7M) |
| Investing Cash Flow | 495.41M | (1.05B) | (165.8M) | 755.56M | 69.64M |
| Debt Repayment | 0 | 304.17M | 0 | (68K) | (162.59M) |
| Common Stock Issued | 548.53M | 0 | 0 | 0 | 36.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (25.01M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.04M | (71.66M) | 125M | 124.87M | (17.06M) |
| Financing Cash Flow | 561.57M | 232.51M | 125M | 124.81M | (168.34M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 613.81M | (1.14B) | (541.79M) | 674.58M | (304.18M) |
| Free Cash Flow | (481.66M) | (357.6M) | (588.34M) | (352.74M) | (307.45M) |
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
Intrinsic Alpha fair value
Locked
Current Price
$14.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.